Authorized purpose: Passive triage notification for adult chest X-ray cases suggestive of pleural effusion.
Clinical role
Analyzes PA chest X-ray images for suspected pleural effusion and sends a passive case-level notification to the PACS/workstation for worklist prioritization or triage; it does not direct attention to image locations and is not for stand-alone decision-making.
Images and patients
X-ray/Radiography · Chest
Key limitation
Keep in mind: Adults age 18 or older and PA chest X-rays only; not standalone clinical decision-making, not a rule-out device, and not intended to preclude clinical assessment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Passive triage notification for adult chest X-ray cases suggestive of pleural effusion.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest Input: DICOM PA chest X-ray images from adults age 18 or older.
Who uses it?Intended users: Radiologists.
What does the software produce?Output: Case-level passive notification to a PACS/workstation for worklist prioritization or triage of suspected pleural effusion; no image marking or localization.
What is its most important limitation?Key limitation: Adults age 18 or older and PA chest X-rays only; not standalone clinical decision-making, not a rule-out device, and not intended to preclude clinical assessment.
Clinical takeaway. Clinical role: Passive triage notification for adult chest X-ray cases suggestive of pleural effusion.
Evidence takeaway. Evidence from the reviewed source record: FDA packet reports internal validation on 1,454 images and standalone testing on 600 images, including 286 positive and 314 negative cases; standalone sensitivity was 0.9510, specificity 0.9745, and AUC 0.9712.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Passive triage notification for adult chest X-ray cases suggestive of pleural effusion.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Analyzes PA chest X-ray images for suspected pleural effusion and sends a passive case-level notification to the PACS/workstation for worklist prioritization or triage; it does not direct attention to image locations and is not for stand-alone decision-making.
Exact FDA submission
Checked 2026-11-14
Packet wording: "analyzes cases using an artificial intelligence algorithm to identify suspected findings on chest x-ray images taken in PA position. It makes case-level output available to a PACS/workstation for worklist prioritization or triage." … "The device is intended to provide a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from the prioritization.". Read from the exact FDA decision document on 2026-11-14.
Case-level passive notification to a PACS/workstation for worklist prioritization or triage of suspected pleural effusion; no image marking or localization.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Adults age 18 or older and PA chest X-rays only; not standalone clinical decision-making, not a rule-out device, and not intended to preclude clinical assessment.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA packet reports internal validation on 1,454 images and standalone testing on 600 images, including 286 positive and 314 negative cases; standalone sensitivity was 0.9510, specificity 0.9745, and AUC 0.9712.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet reports internal validation on 1,454 images and standalone testing on 600 images, including 286 positive and 314 negative cases; standalone sensitivity was 0.9510, specificity 0.9745, and AUC 0.9712.
FDA source
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
EFAI ChestSuite XR Pleural Effusion Assessment System regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K222076
Samplen=600
IndependenceIndependence not established
K222076
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K222076. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM PA chest X-ray images from adults age 18 or older.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the EFAI software as recommended for deployment in a local network, installed on a specialized server supporting deep learning processing, and packaged as a docker container installable on a physical or virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The deployment environment is recommended to be in a local network" … "Assessment System should be installed on a specialized server supporting deep learning processing.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Case-level passive notification to a PACS/workstation for worklist prioritization or triage of suspected pleural effusion; no image marking or localization.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Case-level passive notification to a PACS/workstation for worklist prioritization or triage of suspected pleural effusion; no image marking or localization.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the EFAI software as recommended for deployment in a local network, installed on a specialized server supporting deep learning processing, and packaged as a docker container installable on a physical or virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The deployment environment is recommended to be in a local network" … "Assessment System should be installed on a specialized server supporting deep learning processing.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
Vendor-wide
Checked 2026-10-27
Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for EFAI ChestSuite XR Pleural Effusion Assessment System; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K222076 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Triage and prioritization of adult chest X-ray cases suggestive of vertebral compression fracture, including use in Bone Health and Fracture Liaison Service programs.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.